Vetoquinol SA

V?toquinol is a global player in the animal health sector, serving both the livestock (cattle and pigs) and pet (dogs and cats) markets. Co. designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region, as an independent entity. Co. is also active in the therapeutic fields of anti-infectives, pain-inflammation and cardiology-nephrology treatment. As of Dec 31 2013, Co.'s product portfolio included brands such as Aurizon®, Epiphen®, Ipakitine®, Marbocyl®, Propalin®, Tolf?dine®, Tolfine®, Clavaseptin®, and Vetprofen®. Co.'s brands are V?toquinol, Tomlyn, and Evsco in the U.S.A. and Equistro for the horse range.
  • TickerVETO
  • ISINFR0004186856
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance
Nicolas Thorez

ODDO BHF Small & MIDCAP MORNING NEWS - 10/16/2020

We present our ESG analysis method based on a series of seven risks and seven opportunities covering the three ESG dimensions and the solutions to the major sustainable development challenges. It will gradually be applied to all the companies covered by the financial analyst department and we start with the pharma sector. Based on the most material ESG risks and opportunities in the sector, GSK is our best-in-class pick among the six European Pharma stocks covered by ODDO BHF Securiti...

Christophe-Raphaël Ganet

Vetoquinol : Good Q3 sales with an acceleration at the organic level – Update / target price: € 85

>Q3: the “Essentiels” (51% of sales) continue to drive growth - Q3 revenues (€ 114.5m) rose by 14.3% and 18.9% at constant currency (cc) and by 12.7% l-f-l.Q3 2020 saw the consolidation of Drontal® and Profender®, whilst Clarion (Brazil) no longer has a scope effect (consolidation as of 15 April 2019).All regions reflected growth with organic growth rates of +4%, +16% and +29% respectively for Europe, the Americas and Asia Pacific/rest of the world. In ...

Nicolas Thorez

ODDO BHF Small & MIDCAP MORNING NEWS - 16/10/2020

Nous présentons notre méthode d’analyse fondée sur une grille de 7 risques et 7 opportunités, couvrant les trois dimensions de l'ESG et les solutions aux grands enjeux de développement durable. Nous l’appliquerons progressivement à l'ensemble des valeurs suivies par le bureau d'analyse financière, et commençons ici par le secteur Pharma. Sur la base des risques et opportunités ESG matériels du secteur, notre best-in-class parmi les 6 valeurs européennes Pharma suivies par ODDO BHF est...

Christophe-Raphaël Ganet

Vetoquinol : Bon CA T3 avec une accélération de l’organique –OC relevé à 85 €

>T3 : les «Essentiels» (51% du CA) continuent de porter la croissance - Les revenus du T3 (114,5 M€) progressent de 14,3% et 18,9% à tcc. et 12,7% à ptcc.T3 a vu la consolidation de Drontal® et Profender®, tandis que Clarion (Brésil) ne produit plus d’effet périmètre (intégration au 15 avril 2019).Tous les territoires sont en progression avec des croissances organiques de +4%, +16% et +29% respectivement pour l’Europe, les Amériques et l’Asie Pacifique/reste...

Christophe-Raphaël Ganet

Vetoquinol : Good Q3 sales with an acceleration at the organic level – Update / target price: € 85

>Q3: the “Essentiels” (51% of sales) continue to drive growth - Q3 revenues (€ 114.5m) rose by 14.3% and 18.9% at constant currency (cc) and by 12.7% l-f-l.Q3 2020 saw the consolidation of Drontal® and Profender®, whilst Clarion (Brazil) no longer has a scope effect (consolidation as of 15 April 2019).All regions reflected growth with organic growth rates of +4%, +16% and +29% respectively for Europe, the Americas and Asia Pacific/rest of the world. In ...

Christophe-Raphaël Ganet

Vetoquinol : Bon CA T3 avec une accélération de l’organique –OC relevé à 85 €

>T3 : les «Essentiels» (51% du CA) continuent de porter la croissance - Les revenus du T3 (114,5 M€) progressent de 14,3% et 18,9% à tcc. et 12,7% à ptcc.T3 a vu la consolidation de Drontal® et Profender®, tandis que Clarion (Brésil) ne produit plus d’effet périmètre (intégration au 15 avril 2019).Tous les territoires sont en progression avec des croissances organiques de +4%, +16% et +29% respectivement pour l’Europe, les Amériques et l’Asie Pacifique/reste...

Christophe-Raphaël Ganet

Vetoquinol : H1 2020 sales and c.EBIT ahead of forecasts – Estimates revised upwards – TP lifted to € 70 vs € 64.5

>Q2 sales – H1 c.EBIT better than expected - Q2 sales fared well reaching € 92.7m (+1.9%), or H1 sales of € 196.1m (+6.7% and +7.5% lfl/impact of BRL). We were probably too cautious in our forecasts. Sales in the Household pets division (59% of total sales) were up 6.8% lfl, whereas livestock sales (42%) grew 8.5% lfl. C.EBIT before depreciation of the assets acquired in H1 surged to € 28m (+46%). Net cash at end June (before the acquisition for €/$140m of D...

Christophe-Raphaël Ganet

Vetoquinol : CA et ROC S1 2020 supérieurs à notre attente – Relèvement de nos attentes – OC relevé à 70 € vs 64.5 €

>CA T2 – ROC S1 meilleur qu’attendu - Le CA T2 se comporte bien puisqu’il a atteint 92.7 M€ (+1.9%), soit un CA S1 à 196.1 M€ (+6.7% et +7,5% à ptc./ impact du BRL). Nous étions sans doute trop conservateurs dans nos prévisions.Les animaux de compagnie (58% du CA total) sont en hausse de 6.8% à tcc. pendant que les animaux de rente (42%) progressent de 8.5% à tcc. Le ROC av. amortissement des actifs acquis S1 progresse fortement (+46%) et se situe à 28 M€. Le cas...

MarketLine Department

Dechra Pharmaceuticals Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Dechra Pharmaceuticals Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Dechra Pharmaceuticals Plc since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competit...

Florian Béchaz

Vétoquinol S.A. - Assemblée Générale des actionnaires du 21 mai 2019

Proxinvest attire l'attention des actionnaires sur les points suivants : Tout d'abord, notons que le Conseil d'administration de la société est largement composé par la famille Frechin, actionnaire de contrôle, qui est représentée par 4 sièges sur 8 (50%). Par ailleurs, Proxinvest regrette que la société maintienne la possibilité de l'usage de ses délégations financières en période d'offre publique, ce qui n'est pas favorable aux intérêts des actionnaires puisque cela peut être considéré comme la mise en place d'un arsenal anti-OPA. Enfin, la communication de la société concernant les rémuné...

SRI Quantitative KPIs

Les analyses Gaïa sont des analyses ESG (Environnement, Social, Gouvernance) dediees aux entreprises de tailles intermediaires (PME, ETI) françaises. Elles presentent 120 indicateurs quantitatifs sur les trois derniers exercices.

SRI Company Analysis

Geol analyses are ESG (Environment, Social, Governance) analyses covering European large caps and small and mid caps, listed or non-listed. Those analyses, based on the ESG risks identified, show the qualitative and quantitative performance of issuers, in a ten-page synthesis.

Nicolas Thorez

ODDO BHF Small & MIDCAP MORNING NEWS - 10/16/2020

We present our ESG analysis method based on a series of seven risks and seven opportunities covering the three ESG dimensions and the solutions to the major sustainable development challenges. It will gradually be applied to all the companies covered by the financial analyst department and we start with the pharma sector. Based on the most material ESG risks and opportunities in the sector, GSK is our best-in-class pick among the six European Pharma stocks covered by ODDO BHF Securiti...

Nicolas Thorez

ODDO BHF Small & MIDCAP MORNING NEWS - 16/10/2020

Nous présentons notre méthode d’analyse fondée sur une grille de 7 risques et 7 opportunités, couvrant les trois dimensions de l'ESG et les solutions aux grands enjeux de développement durable. Nous l’appliquerons progressivement à l'ensemble des valeurs suivies par le bureau d'analyse financière, et commençons ici par le secteur Pharma. Sur la base des risques et opportunités ESG matériels du secteur, notre best-in-class parmi les 6 valeurs européennes Pharma suivies par ODDO BHF est...

Christophe Chaput ...
  • Christophe-Raphaël Ganet
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier

ODDO BHF Small & MIDCAP MORNING NEWS - 06/10/2020

ASMi’s story increasingly resembles that of ASML (minus the monopoly). The group benefits from the structural increase in capex for 7nm, 5nm and soon 3nm nodes in more precise deposition techniques (ALD and epitaxy) and is gaining market share in memory. ASMi is now profitable and has enough cash to dispense with ASM PT, which should be an incentive for it to sell its residual 25% stake. This would crystallise the group’s low valuation relative to peers (11.8x EBITDA excluding ASM PT)...

VETOQUINOL loses on its star level and is downgraded to Slightly Positive

The independent financial analyst theScreener just slightly lowered the general evaluation of VETOQUINOL (FR), active in the Pharmaceuticals industry. The title has lost a star(s) at the fundamental level and now shows 2 out of 4 stars. Its exposure to market risk remains nonetheless the same and can be still described as defensive. theScreener slightly downgrades the general evaluation to Slightly Positive for the title on account of the lost star(s). As of the analysis date May 15, 2020, the closing price was EUR 54.00 and its potential was estimated at EUR 65.94.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the we...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch